Wigge & Partners has represented Vimab Holding AB and its owners in connection with Headsent AB (publ)’s (“Headsent”) reverse acquisition of Vimab Holding AB. Headsent has undergone a renewed listing process on Nasdaq First North Growth Market in connection with the transaction and has changed its company name to Vimab Group AB (publ) (“Vimab”). Vimab’s ambition is to become one of the leading groups in the Nordics within sustainable industrial services.
Link to press releases (in Swedish):
The advisory team from Wigge & Partners consisted of Henrik Fritz (Partner), Oliver Cherek (Senior Associate), Kristian Cardell (Associate) and Carl Hedström (Associate).
